表紙
市場調査レポート

米国の体外診断(IVD)市場:新興の償還制度、技術動向、市場動向による戦略的影響

US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends

発行 Venture Planning Group 商品コード 228238
出版日 ページ情報 英文 135 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。

Local License: 同一事業所内

Back to Top
米国の体外診断(IVD)市場:新興の償還制度、技術動向、市場動向による戦略的影響 US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends
出版日: ページ情報: 英文 135 Pages
概要

当レポートでは、米国の体外診断(IVD)市場について調査分析し、主な法規制や、経済的・人口統計的・社会的な動向を概説し、今後5〜10年間の検査件数と売上高の予測を検査場所・分野別に提供し、新興の技術や市場動向なども含め、概略以下の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 結論および提言

第3章 ビジネス環境

  • 医療費
  • コスト意識
  • 償還
  • 業界の統合
  • 病院
  • 入院
  • 入院期間
  • 業界の多様化
  • 医師人口統計
  • 高齢化

第4章 IVD市場の見通し

  • 政府の規制
  • FDAの改革
  • 病院
  • 民間検査所
  • 医局
  • ポイントオブケア検査
  • 個別化検査
  • その他の検査場所

第5章 戦略的影響

  • 検査形態
    • 検査の利用
    • 入院前検査
    • 入院患者の検査
    • 外来検査

第6章 市場セグメント

  • 臨床化学および免疫診断
  • 微生物学および血清学
  • 血液学およびフローサイトメトリー
  • 血液バンキング
  • 組織学および細胞学
  • 血液凝固
  • 尿検査

第7章 技術

  • 分子診断
  • モノクローナル抗体
  • 固相化学
  • バイオセンサーおよびバイオチップ
  • 自動化およびロボット工学
  • IT

第8章 新規市場

  • 購買への影響
  • マーケティング戦略
  • 合弁、合併、ライセンス活動
  • 輸出入
  • 潜在的な市場参入者
  • 生き残れないのは誰か

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: VP3SC19038
How will the future reimbursement changes affect individual market segments?

- Will the industry consolidate, decentralize, or undergo a bimodal transformation?

- What will be the impact on purchasing influences, marketing strategies, joint ventures, mergers, licensing, import and export?

- How will the future technological advances affect the major market segments?

- Which companies will enter the market and which will not survive?

These and other key strategic issues facing decision-makers are explored in this thought-provoking and multi-faceted portrait of the future U.S. in vitro diagnostics market.

This invaluable strategic planning resource is designed to help corporate, marketing and R&D executives develop effective business plans that best accommodate uncertainties ahead. The report evaluates emerging markets and technologies that may present unexpected threats or offer opportunities; identifies key strategic decisions that will have to be made in the future; and enhances corporate ability to develop realistic contingency plans.

The report presents strategic overview of the U.S. in vitro diagnostics market, including major regulatory, economic, demographic and social trends with potentially significant impact; as well as five- and ten-year test volume and sales forecasts for major testing locations (hospitals, commercial labs, physician offices, blood centers, POC sites, and others) and laboratory disciplines (blood banking, clinical chemistry, immunodiagnostics, coagulation, hematology, flow cytometry, histology, cytology, microbiology, serology, urinalysis and others).

Contains 135 pages and 11 tables

Table of Contents

I. Executive Summary

2. Conclusions and Recommendations

3. Business Environment

  • a. Health Care Expenditures
  • b. Cost-Consciousness
  • c. Reimbursement
  • d. Industry Consolidation
  • e. Hospitals
  • f. Admissions
  • g. Length of Stay
  • h. Industry Diversification
  • i. Physician Demographics
  • j. Aging Population
    • More Chronic Illnesses
    • Higher Incidence of Disease
    • Greater Susceptibility to Iatrogenesis
    • More Cases with Multiple Illnesses

4. Outlook for the In Vitro Diagnostics Market

  • a. Government Regulations
  • b. FDA Reform
  • c. Hospitals
  • d. Commercial Laboratories
  • e. Physician Offices
  • f. Point-of-Care Testing
  • g. Personal Testing
  • h. Other Testing Locations

5. Strategic Implications

  • a. Testing Patterns
    • Test Utilization
    • Pre-Admission Testing
    • Inpatient Testing
    • Outpatient Testing

6. Market Segments

  • a. Clinical Chemistry and Immunodiagnostics
    • Introduction
    • Future Situation
  • b. Microbiology and Serology
    • Introduction
    • Future Situation
  • c. Hematology and Flow Cytometry
    • Introduction
    • Future Situation
  • d. Blood Banking
    • Introduction
    • Future Situation
  • e. Histology and Cytology
    • Introduction
    • Future Situation
  • f. Coagulation
    • Introduction
    • Future Situation
  • g. Urinalysis
    • Introduction
    • Future Situation

7. Technologies

  • a. Molecular Diagnostics
    • Introduction
    • Future Situation
  • b. Monoclonal Antibodies
    • Introduction
    • Future Situation
  • c. Solid Phase Chemistry
    • Introduction
    • Future Situation
  • d. Biosensors and Biochips
    • Introduction
    • Future Situation
  • e. Automation and Robotics
    • Introduction
    • Future Situation
  • f. IT
    • Introduction
    • Future Situation

8. The New Marketplace

  • a. Purchasing Influences
  • b. Marketing Strategies
  • c. Joint Venture, Merger, and Licensing Activity
  • d. Import-Export
  • e. Potential Market Entrants
  • f. Who May Not Survive?

List of Tables

  • Executive Summary Table: Growth Areas in Clinical Laboratory Testing
  • Table-1: Estimated U.S. Health Care Expenditures By Expenditure Type
  • Table-2: Health Plan Enrollment Distribution
  • Table-3: Selected Hospital Statistics
  • Table-4: Total Population And Physician Demographics
  • Table-5: Test Volume By Location
  • Table-6: Test Distribution By Location
  • Table-7: Market Size By Location
  • Table-8: Typical Pre-Admission Tests
  • Table-9: Test Volume By Laboratory Discipline
  • Table-10: Market Size By Laboratory Discipline
Back to Top